Estrogenicity of essential oils is not required to relieve symptoms of urogenital atrophy in breast cancer survivors.
AuthorsSimões, Bruno M
Clarke, Robert B
Armstrong, Anne C
Howell, Sacha J
AffiliationBreast Cancer Now Research Unit, Division of Cancer Sciences, University of Manchester, Manchester, UK
MetadataShow full item record
AbstractUrogenital atrophy (UA) is a common treatment-limiting side effect of endocrine therapies. Topical estrogen is effective but systemic absorption may counter aromatase inhibitor efficacy. Numerous complementary approaches are marketed for use in UA without rigorous testing of their estrogenicity. We tested multiple essential oils in cancer cell growth and estrogen reporter assays in vitro and assessed clinical outcomes with the essential oil pessaries (EOPs) in breast cancer survivors with UA.
CitationEstrogenicity of essential oils is not required to relieve symptoms of urogenital atrophy in breast cancer survivors. 2018, 10:1758835918766189 Ther Adv Med Oncol
JournalTherapeutic Advances in Medical Oncology